Medscape Medical News (08.12.2013)
The US Food and Drug Administration recently approved a new drug called dolutegravir (brand name Tivicay by GlaxoSmithKline) for the treatment of HIV. Tivicay is an integrase strand transfer inhibitor, which blocks an enzyme that the virus needs to reproduce itself. The drug is in the form of a once-daily pill taken in combination with other antiretrovirals. The drug was approved for use by treatment-naïve adults, adults already using antiretroviral drugs (ART), and youth 12 years and over weighing at least 40 kilograms (88.2 lbs.) who have or have not received ART, but who have never taken an integrase strand transfer inhibitor. The drug was tested for safety and efficacy on 2,539 participants, and results show that Tivicay, when used with other ARTs, was effective in reducing viral loads. Side effects included insomnia and headache hypersensitivity reactions, and abnormal liver function in individuals coinfected with hepatitis C and B.